Cervical Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Cervical cancer is one of the most common malignancies in the female genital tract system. It is the second leading cause of cancer mortality in women aged 20 to 39 years. The prognosis of cervical cancer patients remains poor, especially in metastatic patients. Previous studies have shown that the median survival time of metastatic cervical cancer is only 8-13 months, and the 5-year survival rate is 16.5%. Due to the poor prognosis, metastatic cervical cancer has become one of the main challenges in the world. In metastatic and recurrent Cervical cancer, Single-site metastasis accounted for 68.7%, and multi-organ metastases were relatively rare. In single-site metastasis, lung metastasis was the most common, accounting for 37.9% of all patients, followed by bone metastasis (16.7%) and liver metastasis (12.5%).
·
Brain metastases were uncommon, only accounted
for 1.6%. In patients with multi-organ metastases, lung plus liver metastases
and lung plus bone metastases were more common than other multi-organ
metastases.
Thelansis’s “Cervical Cancer Market
Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2021 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Cervical Cancer treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Cervical Cancer across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Cervical Cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment